Vaccines Articles
GlaxoSmithKline has developed a new shingles vaccine that is 97 percent effective in adults ages 50 years to 70 years.
Recent research has found a new approach to stimulate the skin immune response to fight various pathogens with an easy-to-use needle-free vaccine.
At the end of February, the Centers forDisease Control and Prevention (CDC)reported that the 2014-15 seasonal influenza vaccine was just 18 percent effective against the dominant strain of flu.
An analysis of 67 research studies published in the July 1 edition of Pediatrics has found that serious complications related to vaccines are very rare, and there is no evidence that immunizations cause autism.
bioCSL has announced the donation of more than 700,000 doses of its influenza vaccine to the Partnership for Influenza Vaccine Introduction.
The Advisory Committee on Immunization Practices voted 15 to 0 to recommend a preference for the inhaled live attenuated influenza vaccine, FluMist Quadrivalent, for healthy children ages 2 years through 8 years.
The U.S. Food and Drug Administration (FDA) has approved PharmaJet Inc.’s Stratis 0.5mL Needle-Free Jet Injector for delivery of bioCSL Inc.’s AFLURIA influenza vaccine for individuals ages 18 to 64 years.
The National Institutes of Health began human testing of an ebola vaccine in a Phase I clinical trial in September.
The Centers for Disease Control and Prevention found that vaccination coverage among adolescents ages 13 to 17 years rose between 2012 and 2013.
According to the U.S. Centers for Disease Control and Prevention, adult vaccination coverage remains well below Healthy People 2020 targets.
Update on HIV/AIDS, meningococcal Group B, tetanus, diphtheria, pertussis and dengue vaccines.
A recent study shows that a vaccine typically used to prevent tuberculosis in countries outside of the U.S. could also prevent multiple sclerosis (MS) in people who are in the beginning stages of the disease.
